BioMarin Pharmaceutical Dividendi e riacquisti
Criteri Dividendo verificati 0/6
BioMarin Pharmaceutical non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
0.3%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | 0.3% |
| Rendimento futuro dei dividendi | 0% |
| Crescita dei dividendi | n/a |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | n/a |
Aggiornamenti recenti su dividendi e riacquisti
Nessun aggiornamento
Recent updates
Aggiornamento della narrazione • May 14
BMRN: Pending Amicus Acquisition Will Recast Earnings Power Despite Treatment Franchise Uncertainty
Analysts have nudged their fair value estimate for BioMarin Pharmaceutical to $89.96, reflecting updated assumptions on discount rate, revenue growth, profit margins, and a higher future P/E following a mix of recent price target increases and reductions across the Street. Analyst Commentary Street research on BioMarin Pharmaceutical has been active, with a mix of higher and lower price targets and one recent coverage reinstatement at Goldman Sachs.Seeking Alpha • May 06
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
Summary BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026. The BMN 401 and BMN 333 programs, alongside PALYNZIQ label expansion, further diversify BMRN's growth opportunities and de-risk the investment thesis. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 29
BMRN: Fair Value View Weighs Voxzogo Headwinds Against Amicus Acquisition Potential
Analysts have trimmed their average price target on BioMarin Pharmaceutical slightly, cutting fair value by about $0.30 to $55.36. They are factoring in a higher discount rate, modestly stronger long term growth and margins, and a slightly lower future P/E multiple following recent reassessments of the Voxzogo franchise and the planned Amicus acquisition.Aggiornamento della narrazione • Apr 15
BMRN: Fair Value View Balances Voxzogo Risks And Amicus Opportunity
The analyst fair value estimate for BioMarin Pharmaceutical has been trimmed from about $60 to roughly $55.66 as analysts factor in a higher discount rate, a lower future P/E multiple, and mixed expectations around Voxzogo and the Amicus acquisition. Analyst Commentary Recent research on BioMarin reflects a mixed but generally constructive stance, with several firms revising price targets while keeping positive ratings.Aggiornamento della narrazione • Apr 01
BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks
Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged. Analyst Commentary Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures.Aggiornamento della narrazione • Mar 18
BMRN: Amicus Acquisition Is Expected To Reshape Future Earnings Power
Analysts have nudged their fair value estimate for BioMarin to $88.96 from $88.65, citing updates to revenue growth, profit margin and future P/E assumptions as they reassess Voxzogo risks, competitive pressure and the potential impact of the Amicus acquisition. Analyst Commentary Recent street research paints a mixed picture for BioMarin, with analysts recalibrating expectations around Voxzogo, the Amicus acquisition and the broader rare disease portfolio.
Aggiornamento della narrazione • Mar 03
BMRN: Rare Disease Portfolio Expansion And Amicus Acquisition Will Drive Repricing
Our BioMarin Pharmaceutical update trims the fair value estimate slightly to $120 from $122, as analysts weigh higher long term growth and margin assumptions against a higher discount rate and a lower future P/E multiple. Recent Street price target moves now cluster in the mid to high $90s, with outliers as low as $55 and as high as $105.Aggiornamento della narrazione • Feb 17
BMRN: Recent Coverage Shifts Will Support Higher Future Earnings Multiple
Analysts have trimmed their fair value estimate for BioMarin Pharmaceutical by roughly $2 to about $88.65. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions drawn from recent Street research.Aggiornamento della narrazione • Feb 03
BMRN: Shares Should Recover As Fresh Coverage Supports Higher Future Earnings Multiple
Analysts have lifted their price target for BioMarin Pharmaceutical by about US$1 to roughly US$91, citing updated assumptions around revenue growth, margins and a higher future P/E multiple, supported by recent positive Street research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Street coverage as support for using a higher future P/E multiple, which feeds directly into a slightly higher fair value range around US$91.Aggiornamento della narrazione • Jan 20
BMRN: Reset Long Term Outlook Will Shape Risk Balance Going Forward
Analysts have reduced their price target on BioMarin Pharmaceutical to US$60 from US$67.39 as they factor in updated long term revenue scenarios, a higher discount rate, and slightly stronger margin assumptions following recent quarterly results and guidance changes. Analyst Commentary Recent Street research shows a cluster of price target cuts on BioMarin, generally following an "okay" Q3 print, a Q3 revenue miss in some areas, and updated long term guidance that now reflects a wider range of possible competitive and intellectual property outcomes.Aggiornamento della narrazione • Jan 06
BMRN: Shares Should Recover As 2027 Revenue Reset Clarifies Competition Risk
Analysts now see fair value for BioMarin Pharmaceutical at $89.74 per share, a small move up that reflects lower long term revenue growth assumptions, a slightly higher profit margin outlook, and modestly higher future P/E expectations following recent price target cuts tied to Voxzogo trends, revised 2027 revenue guidance, and potential competition. Analyst Commentary Recent Street research shows a wide range of views on BioMarin, with a clear focus on Voxzogo trends, updated 2027 revenue scenarios, and the impact of potential competition on execution and valuation.Aggiornamento della narrazione • Dec 16
BMRN: Shares Will Strengthen As 2025 Guidance Reset Supports Future Upside
Analysts have trimmed their average price target on BioMarin Pharmaceutical by roughly $1 to reflect a modest reset in long term revenue and margin expectations after Q3’s revenue miss, Voxzogo softness and greater acknowledgment of emerging competitive risks, even though they continue to view the shares as undervalued. Analyst Commentary Analyst reactions to BioMarin’s Q3 update reflect a more nuanced view of the company’s medium term growth profile, with reduced price targets but largely constructive ratings as investors recalibrate for competitive dynamics and updated long range guidance.Aggiornamento della narrazione • Dec 02
BMRN: Shares Will Strengthen As 2025 Guidance and Pipeline Progress Drive Upside
BioMarin Pharmaceutical's analyst price target has been reduced from $90.50 to $89.36. Analysts cite slightly lower growth and profit margin expectations, new competitive pressures, and revised long-term guidance as key drivers for the change.Aggiornamento della narrazione • Nov 18
BMRN: Shares Will Recover As Revenue Guidance Aligns With Market Expectations
Analysts have modestly reduced their price target for BioMarin Pharmaceutical, trimming it by $0.10 to $90.50. Recent updates reflect a more cautious outlook on revenue growth and profit margins in light of evolving competitive and regulatory expectations.Aggiornamento della narrazione • Nov 03
BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead
Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.Articolo di analisi • Oct 30
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its quarterly result to the...Aggiornamento della narrazione • Oct 20
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.Aggiornamento della narrazione • Oct 05
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.Articolo di analisi • Aug 06
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
NasdaqGS:BMRN 1 Year Share Price vs Fair Value Explore BioMarin Pharmaceutical's Fair Values from the Community and...Articolo di analisi • Jul 22
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc.'s ( NASDAQ:BMRN ) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a...Seeking Alpha • Jan 23
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Summary BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's day, and competition with their drug VOXZOGO. The sharp decline in share price invites a reassessment of BioMarin's current investment prospects. Investors need to weigh the potential for recovery against the risks of further declines. Read the full article on Seeking AlphaSeeking Alpha • Nov 21
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Summary Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth. Elliott Investment Management is invested in the company and may be attempting to position the business for a sale. Management's forecasts may be over-ambitious, and Wall Street's current valuation of the business too low. The prospect of a sale tips the balance in favour of a "Buy" recommendation. Read the full article on Seeking AlphaSeeking Alpha • Aug 21
BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Summary BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end of 2024. The global Duchenne Muscular Dystrophy Treatment market size is expected to reach $8.19 billion by 2029; It is said that about 13% of DMD patients are amenable to exon 51 skipping. Read the full article on Seeking AlphaSeeking Alpha • Jul 24
BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Summary BioMarin's shares have enjoyed three strong, albeit brief, updrafts in recent years. It plans to reveal its latest strategies for developing its rich portfolio of approved drugs at its 09/2024 investor's day. With ample liquidity and positive earnings BioMarin's financial profile is steady. Read the full article on Seeking AlphaSeeking Alpha • May 15
BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
Summary BioMarin's 1Q24 revenue was $649 million, with a 9% YoY increase, but uncertainty around the commercial prospects of Roctavian has dampened optimism. The company's core drug portfolio performed as expected, with some drugs exceeding consensus expectations and others falling short. Voxzogo remains a strong revenue driver, with sales of $153 million in 1Q24, and plans to expand into new indications, potentially significantly expanding the addressable market. I maintain my bullish view on BMRN stock, but it has become less bullish. My new fair price for BMRN is $112. Read the full article on Seeking AlphaStabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BMRN siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BMRN siano aumentati.
Rendimento dei dividendi rispetto al mercato
| BioMarin Pharmaceutical Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (BMRN) | n/a |
| Fondo del 25% del mercato (US) | 1.4% |
| Top 25% del mercato (US) | 4.3% |
| Media del settore (Biotechs) | 2.4% |
| Analista previsionale (BMRN) (fino a 3 anni) | 0% |
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BMRN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BMRN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BMRN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BMRN non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 12:19 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
BioMarin Pharmaceutical Inc. è coperta da 48 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Eliana Merle | Barclays |